Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 607

1.

Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling Adaptor DAP12.

Kameda Y, Takahata M, Komatsu M, Mikuni S, Hatakeyama S, Shimizu T, Angata T, Kinjo M, Minami A, Iwasaki N.

J Bone Miner Res. 2013 Dec;28(12):2463-75. doi: 10.1002/jbmr.1989.

2.

Siglec-15 is a potential therapeutic target for postmenopausal osteoporosis.

Kameda Y, Takahata M, Mikuni S, Shimizu T, Hamano H, Angata T, Hatakeyama S, Kinjo M, Iwasaki N.

Bone. 2015 Feb;71:217-26. doi: 10.1016/j.bone.2014.10.027. Epub 2014 Nov 8.

PMID:
25460183
3.

Siglec-15 protein regulates formation of functional osteoclasts in concert with DNAX-activating protein of 12 kDa (DAP12).

Ishida-Kitagawa N, Tanaka K, Bao X, Kimura T, Miura T, Kitaoka Y, Hayashi K, Sato M, Maruoka M, Ogawa T, Miyoshi J, Takeya T.

J Biol Chem. 2012 May 18;287(21):17493-502. doi: 10.1074/jbc.M111.324194. Epub 2012 Mar 26.

5.

Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) mediates periarticular bone loss, but not joint destruction, in murine antigen-induced arthritis.

Shimizu T, Takahata M, Kameda Y, Endo T, Hamano H, Hiratsuka S, Ota M, Iwasaki N.

Bone. 2015 Oct;79:65-70. doi: 10.1016/j.bone.2015.05.029. Epub 2015 May 28.

PMID:
26027508
6.

Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis.

Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, Iwata T, Ohnishi H, Matozaki T, Kodama T, Taniguchi T, Takayanagi H, Takai T.

Nature. 2004 Apr 15;428(6984):758-63.

PMID:
15085135
7.

Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.

Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M.

J Bone Miner Res. 2011 Mar;26(3):644-56. doi: 10.1002/jbmr.242.

8.

Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.

Yi T, Lee HL, Cha JH, Ko SI, Kim HJ, Shin HI, Woo KM, Ryoo HM, Kim GS, Baek JH.

J Cell Physiol. 2008 Nov;217(2):409-22. doi: 10.1002/jcp.21511.

PMID:
18543257
9.

TREM2, a DAP12-associated receptor, regulates osteoclast differentiation and function.

Humphrey MB, Daws MR, Spusta SC, Niemi EC, Torchia JA, Lanier LL, Seaman WE, Nakamura MC.

J Bone Miner Res. 2006 Feb;21(2):237-45. Epub 2005 Oct 20.

10.

Signal adaptor DAP10 associates with MDL-1 and triggers osteoclastogenesis in cooperation with DAP12.

Inui M, Kikuchi Y, Aoki N, Endo S, Maeda T, Sugahara-Tobinai A, Fujimura S, Nakamura A, Kumanogoh A, Colonna M, Takai T.

Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4816-21. doi: 10.1073/pnas.0900463106. Epub 2009 Feb 27.

12.

Impaired osteoclast differentiation and function and mild osteopetrosis development in Siglec-15-deficient mice.

Hiruma Y, Tsuda E, Maeda N, Okada A, Kabasawa N, Miyamoto M, Hattori H, Fukuda C.

Bone. 2013 Mar;53(1):87-93. doi: 10.1016/j.bone.2012.11.036. Epub 2012 Dec 11.

PMID:
23238125
13.

TGF-β inducible early gene 1 regulates osteoclast differentiation and survival by mediating the NFATc1, AKT, and MEK/ERK signaling pathways.

Cicek M, Vrabel A, Sturchio C, Pederson L, Hawse JR, Subramaniam M, Spelsberg TC, Oursler MJ.

PLoS One. 2011 Mar 14;6(3):e17522. doi: 10.1371/journal.pone.0017522.

14.

A Comprehensive Review of Immunoreceptor Regulation of Osteoclasts.

Humphrey MB, Nakamura MC.

Clin Rev Allergy Immunol. 2016 Aug;51(1):48-58. doi: 10.1007/s12016-015-8521-8. Review.

15.

The signaling adapter protein DAP12 regulates multinucleation during osteoclast development.

Humphrey MB, Ogasawara K, Yao W, Spusta SC, Daws MR, Lane NE, Lanier LL, Nakamura MC.

J Bone Miner Res. 2004 Feb;19(2):224-34. Epub 2003 Dec 16.

16.

Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling.

Yamashita M, Otsuka F, Mukai T, Yamanaka R, Otani H, Matsumoto Y, Nakamura E, Takano M, Sada KE, Makino H.

Regul Pept. 2010 Jun 8;162(1-3):99-108. doi: 10.1016/j.regpep.2010.03.003. Epub 2010 Mar 24.

PMID:
20346376
17.

Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.

Yuan FL, Xu RS, Jiang DL, He XL, Su Q, Jin C, Li X.

Bone. 2015 Jun;75:128-37. doi: 10.1016/j.bone.2015.02.017. Epub 2015 Feb 21.

PMID:
25708053
18.

Low-density lipoprotein receptor deficiency causes impaired osteoclastogenesis and increased bone mass in mice because of defect in osteoclastic cell-cell fusion.

Okayasu M, Nakayachi M, Hayashida C, Ito J, Kaneda T, Masuhara M, Suda N, Sato T, Hakeda Y.

J Biol Chem. 2012 Jun 1;287(23):19229-41. doi: 10.1074/jbc.M111.323600. Epub 2012 Apr 12.

19.

Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling.

Kalliolias GD, Zhao B, Triantafyllopoulou A, Park-Min KH, Ivashkiv LB.

Arthritis Rheum. 2010 Feb;62(2):402-13. doi: 10.1002/art.27200.

20.

BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.

Valverde P, Tu Q, Chen J.

J Bone Miner Res. 2005 Sep;20(9):1669-79. Epub 2005 May 16.

Supplemental Content

Support Center